EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Takeshi Kawarabayashi iD, Takumi Nakamura iD, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda und 2 weitere

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70359 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Takeshi Kawarabayashi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Dementia Research Center, Geriatrics Research Institute and Hospital, Maebashi, Japan. Hauptthemen laut MEDLINE: tau Proteins, Hydrocephalus, Normal Pressure, Alzheimer Disease, Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants for Scientific Research (C) from the Ministry of Education, Science, and Culture of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.

Methods

Plasma p‐217tau levels were measured in 298 participants, consisting of 81 AD patients, 204 patients with 12 other neurological diseases, and 13 healthy and cognitively unimpaired controls (HCU), using an assay system from Meso Scale Diagnostics. Cerebrospinal fluid (CSF) tau and Aß levels were simultaneously evaluated in AD, amyotrophic lateral sclerosis (ALS), and idiopathic normal pressure hydrocephalus (iNPH).

Results

Plasma p‐217tau levels increased in AD with the clinical stage, but also in ALS and iNPH, leading to them having decreased sensitivity and specificity for diagnosing AD. No increases in plasma p‐217tau levels were seen in possible tauopathies or synucleinopathies. CSF and plasma p‐217tau levels were strongly correlated in AD, but not in ALS. The plasma p‐217tau/CSF p‐217tau ratio was inversely higher in ALS than in AD. Active and chronic denervation potentials were associated with plasma p‐217tau levels. In iNPH, plasma p‐217tau was associated with cognitive dysfunction, but not with gait disturbance or urinary incontinence. CSF p‐181tau, total tau, and Aß1‐40 levels and the Aß1‐40/1–42 ratio were reduced in iNPH.

Interpretation

ALS and iNPH are two major pitfalls for the clinical application of plasma p‐217tau as a biomarker of AD. Lower motor neuron injury in ALS and cognitive dysfunction in iNPH were both found to be associated with elevated plasma p‐217tau levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsHydrocephalus, Normal PressureAlzheimer DiseaseAmyotrophic Lateral SclerosisNervous System DiseasesHumansFemaleMaleBiomarkersAgedAmyloid beta-PeptidesMiddle AgedSensitivity and SpecificityAged, 80 and overReproducibility of Results

Stichwörter der Autor:innen

Alzheimer's diseaseamyotrophic lateral sclerosisidiopathic normal pressure hydrocephalusplasma p‐taup‐tau217

Substanzen

tau ProteinsBiomarkersAmyloid beta-PeptidesMAPT protein, human

Autor:innen und Institutionen

  • Department of Neurology, Dementia Research Center, Geriatrics Research Institute and Hospital, Maebashi, Japan.
  • Department of Neurology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Department of Social Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Analytical Research Center, Mediford Corporation, Tokyo, Japan.

ORCID-Profile: Takeshi Kawarabayashi, Takumi Nakamura, Mikio Shoji

Förderung

  • Grants for Scientific Research (C) from the Ministry of Education, Science, and Culture of Japan

Zitieren

APA

Kawarabayashi, T., Nakamura, T., Takahashi, R., Ueda, T., Kinoshita, S., Uchida, C., Sugawara, T., Hashimoto, K., Ishizawa, K., Amari, M., Kasahara, H., Ikeda, Y., Takatama, M., & Shoji, M. (2026). Clinical Validation of Plasma p‐217tau in Neurological Diseases. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70359

Vancouver

Kawarabayashi T, Nakamura T, Takahashi R, Ueda T, Kinoshita S, Uchida C, et al. Clinical Validation of Plasma p‐217tau in Neurological Diseases. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70359

BibTeX
@article{Kawarabayashi2026,
  author = {Kawarabayashi, Takeshi and Nakamura, Takumi and Takahashi, Ryoma and Ueda, Tetsuya and Kinoshita, Seiji and Uchida, Chikage and Sugawara, Takashi and Hashimoto, Kentaro and Ishizawa, Kunihiko and Amari, Masakuni and Kasahara, Hiroo and Ikeda, Yoshio and Takatama, Masamitsu and Shoji, Mikio},
  title = {Clinical Validation of Plasma p‐217tau in Neurological Diseases},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70359}
}
Kostenlos starten →